Roche Cytovene I.V. shortage lengthens
Executive Summary
Roche expects "intermittent complete out-of-stock situations" for Cytovene I.V. to continue until the middle of the second quarter. "Despite the implementation of a system to manage the available stock, demand exceeds our ability to supply" ganciclovir, a Feb. 6 "Dear Doctor" letter says. Roche had expected to resolve the shortage of the CMV retinitis product by the second quarter (1"The Pink Sheet" Jan. 14, p. 19)....
You may also be interested in...
Cytovene I.V. Shortage Will Be Resolved by Second Quarter, Roche Says
Roche expects to resolve a shortage of Cytovene I.V. by the second quarter
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.